F-NOTA-NFB PET/MRI in glioma recurrence: comparison with C-methionine PET/MRI and contrast-enhanced MRI.

PURPOSE

To investigate the clinical utility of F-NOTA-NFB PET/MRI relative to C-methionine (C-MET) PET/MRI and contrast-enhanced MRI (CE-MRI) for glioma recurrence detection.

METHODS

Patients with suspected recurrence of glioma were prospectively enrolled. All patients underwent paired F-NOTA-NFB and C-MET PET/MRI. Diagnostic efficiency of glioma recurrence detection by different imaging methods were assessed and compared. The suspected lesions showed via F-NOTA-NFB and C-MET PET/MRI were compared by SUVmax and tumor-to-background ratio (TBR). The diagnostic performance of F-NOTA-NFB and C-MET SUVmax/TBR was tested by receiver operating characteristic curve.

RESULTS

Thirty-eight patients with suspected recurrent glioma were included, with 28 positive for recurrent gliomas and 10 negative for recurrence which were confirmed by the pathology or clinical follow-up. For visual assessment, the accuracy and specificity of F-NOTA-NFB PET were equivalent to C-MET PET (accuracy: 92.11% vs. 94.74%, P = 1.00; specificity: 70.00% vs. 80.00%, P = 1.00) and higher than CE-MRI (accuracy: 92.11% vs. 76.32%, P = 0.031; specificity: 70.00% vs. 10.00%, P = 0.031). For quantitative analysis, in recurrent gliomas, F-NOTA-NFB PET revealed higher SUVmax (P = 0.007) and TBR (P = 0.002) than treatment-related effects, with higher TBR for recurrence than that of C-MET (P < 0.001). Although C-MET SUVmax had the highest AUC of 0.911 for detecting glioma recurrence, but with no significant difference relative to C-MET TBR (AUC = 0.889, P = 0.75), F-NOTA-NFB SUVmax (AUC = 0.793, P = 0.32), and F-NOTA-NFB TBR (AUC = 0.829, P = 0.42).

CONCLUSION

The diagnostic efficacy of F-NOTA-NFB PET or PET/MRI performed equivalent to C-MET PET or PET/MRI, and better than CE-MRI for diagnosis of recurrent gliomas. Compared to C-MET, F-NOTA-NFB PET/MRI exhibited higher TBR, giving advantages in glioma delineation that might provide valuable information for making treatment strategy.